---
title: Scribe Therapeutics (SCTX) Targets $100 Million IPO to Advance Next-Generation CRISPR Medicines for Cardiovascular Disease
description: Clinical-stage gene editing company looks to redefine cardiovascular care with proprietary CRISPR technologies designed for durable, scalable genetic medicines.
---

[blog](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y)

# [Scribe Therapeutics (SCTX) Targets $100 Million IPO to Advance Next-Generation CRISPR Medicines for Cardiovascular Disease](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/scribe-therapeutics-sctx-targets-100-million-ipo-to-advance-next-generation-crispr-medicines-for-cardiovascular-disease)

 Written by [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) | Jul 20, 2026 4:37:27 PM

**Scribe Therapeutics (NASDAQ: SCTX)** has filed for an initial public offering of **7.15 million shares** priced between **$13.00 and $15.00 per share**, targeting gross proceeds of approximately **$100.1 million** at the midpoint of the range. At a midpoint price of **$14.00**, Scribe would debut with an implied market capitalization of approximately **$226.5 million** based on **16.18 million shares outstanding** following the offering and concurrent private placement. The IPO is being led by **Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities.**

Founded by **Nobel Prize-winning CRISPR pioneer Dr. Jennifer Doudna**, alongside CEO **Dr. Benjamin Oakes** and a team of leading gene-editing scientists, Scribe Therapeutics is developing a new generation of **in vivo CRISPR-based genetic medicines** aimed at treating some of the world's most common cardiovascular and metabolic diseases. Rather than focusing solely on rare genetic disorders, the company is engineering therapies for large patient populations suffering from elevated cholesterol, lipoprotein(a), and triglycerides using its proprietary **"CRISPR by Design"** platform, which integrates artificial intelligence, machine learning, and large-scale experimental validation to optimize gene-editing performance.

Scribe's lead product candidate, **STX-1150**, utilizes the company's proprietary **ELXR** epigenetic silencing technology to suppress the **PCSK9** gene responsible for elevated LDL cholesterol without permanently altering the underlying DNA sequence. Unlike traditional CRISPR editing approaches that permanently modify genes, ELXR is designed to provide durable cholesterol reduction through reversible epigenetic regulation, potentially offering an improved safety profile while maintaining long-lasting therapeutic benefit. The company recently initiated its first-in-human clinical trial in Australia after receiving regulatory clearance, with initial safety, tolerability, and LDL cholesterol reduction data expected during the **first half of 2027.**

Beyond STX-1150, Scribe is advancing two additional wholly owned cardiovascular programs. **STX-1200** targets elevated **lipoprotein(a) (Lp(a))**, while **STX-1400** targets **APOC3** to reduce triglycerides. Both candidates utilize the company's proprietary **XE** gene-editing platform and have demonstrated encouraging preclinical data, including durable target suppression and no detectable off-target editing across extensive safety analyses. Together, the three programs position Scribe to address several of the largest remaining unmet needs in cardiovascular medicine.

The company's technology has also attracted validation from several of the world's largest pharmaceutical companies. **Sanofi** has agreed to purchase approximately **$7.5 million** of common stock through a concurrent private placement, while **Eli Lilly** has indicated interest in purchasing additional shares in the IPO that could increase its ownership to as much as **10.9%** following the offering. Scribe has also generated more than **$180 million** in collaboration payments, milestones, and research funding through strategic partnerships with Sanofi and Lilly, providing meaningful non-dilutive capital while advancing additional CRISPR programs outside its wholly owned pipeline.

Financially, Scribe remains a clinical-stage biotechnology company with no commercial products. **Collaboration revenue increased to $51.2 million in 2025 from $27.4 million in 2024**, reflecting progress under its pharmaceutical partnerships, while the company's **net loss improved to $21.8 million from $47.8 million** over the same period. Management reported approximately **$43.0 million** in preliminary cash, cash equivalents, and short-term investments as of **June 30, 2026**, prior to the IPO. Net proceeds from the offering are expected to fund continued clinical development of **STX-1150**, advancement of **STX-1200** and **STX-1400**, expansion of the company's CRISPR technology platform, and general corporate purposes.

Scribe Therapeutics enters the public markets as one of the more differentiated companies in the gene-editing sector. By focusing on **common cardiovascular diseases** rather than rare disorders and developing technologies designed to deliver durable therapeutic effects without permanent genetic modification, the company is attempting to expand CRISPR's commercial opportunity into significantly larger patient populations. While clinical execution remains the primary risk, Scribe's combination of a proprietary technology platform, high-profile scientific founders, strategic pharmaceutical partnerships, and multiple wholly owned cardiovascular programs positions it as an IPO that gene-editing and biotechnology investors will likely watch closely.

*Scribe Therapeutics will make it's Nasdaq debut on Friday, July 24th.*  

[View full post](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/scribe-therapeutics-sctx-targets-100-million-ipo-to-advance-next-generation-crispr-medicines-for-cardiovascular-disease)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Eric Friedman"
  },
  "dateModified" : "2026-07-20T16:37:27.069Z",
  "datePublished" : "2026-07-20T16:37:27Z",
  "headline" : "Scribe Therapeutics (SCTX) Targets $100 Million IPO to Advance Next-Generation CRISPR Medicines for Cardiovascular Disease",
  "image" : {
    "@type" : "ImageObject",
    "height" : 776,
    "url" : "https://43826620.fs1.hubspotusercontent-na1.net/hubfs/43826620/Scribe%20Therapeutics%20Thumbnail.jpg",
    "width" : 1688
  },
  "mainEntityOfPage" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/scribe-therapeutics-sctx-targets-100-million-ipo-to-advance-next-generation-crispr-medicines-for-cardiovascular-disease",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "blog"
  }
}
```